Award
National Institute of Arthritis and Musculoskeletal and Skin Diseases 11192350
Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial (The CORK trial)
Recipient
University of Michigan at Ann Arbor
Award Amount
$1,109,271.00
Ceiling
$1,109,271.00
Awarded
August 28, 2025
Identifier
11192350
A clinical trial funded by NIAMS to study the effect of cannabidiol on reducing opioid use after knee surgery, involving 380 patients and lasting from 2023 to 2028 with a budget of about $1.1 million.
Description
The project aims to evaluate the efficacy of CBD in reducing opioid consumption post-surgery. The study involves 380 patients undergoing primary total knee arthroplasty. The trial is multi-site, double-blind, and randomized. The primary outcome is postoperative opioid consumption over 4 weeks. The study will also investigate CBD's effects on anxiety, sleep disturbance, and inflammation. The study drug, Epidiolex, is FDA-approved for certain seizure disorders. The project is funded by NIAMS under grant number 5U01AR083132-03. The project duration is from September 2023 to August 2028. The total funding is approximately $1.1 million. The project involves collaboration with the University of Michigan at Ann Arbor.